Cargando…
The effects of provider-prescribed obesogenic drugs on post-laparoscopic sleeve gastrectomy outcomes: A retrospective cohort study
BACKGROUND: Laparoscopic sleeve gastrectomy (LSG) is one of the most commonly performed bariatric procedures and has proven effective in providing weight loss. However, considerable variance has been noted in the degree of weight loss. Physician prescription practices may be negatively affecting wei...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428627/ https://www.ncbi.nlm.nih.gov/pubmed/30242239 http://dx.doi.org/10.1038/s41366-018-0207-x |
_version_ | 1783405422586101760 |
---|---|
author | Leggett, Cecilia B. Desalermos, Athanasios Brown, Steven D. Lee, Euyhyun Proudfoot, James A. Horgan, Santiago Gupta, Samir Grunvald, Eduardo Ho, Samuel B. Zarrinpar, Amir |
author_facet | Leggett, Cecilia B. Desalermos, Athanasios Brown, Steven D. Lee, Euyhyun Proudfoot, James A. Horgan, Santiago Gupta, Samir Grunvald, Eduardo Ho, Samuel B. Zarrinpar, Amir |
author_sort | Leggett, Cecilia B. |
collection | PubMed |
description | BACKGROUND: Laparoscopic sleeve gastrectomy (LSG) is one of the most commonly performed bariatric procedures and has proven effective in providing weight loss. However, considerable variance has been noted in the degree of weight loss. Physician prescription practices may be negatively affecting weight loss post-LSG and, thus, contributing to the broad range of weight loss outcomes. The aim of our study was to determine whether commonly prescribed obesogenic medications negatively affect weight loss outcomes post-LSG. SUBJECTS/METHODS: This single center retrospective cohort study performed at a University hospital included 323 patients (≥18 years) within University California, San Diego Healthcare System who underwent LSG between 2007 and 2016. We identified a list of 32 commonly prescribed medications that have weight gain as a side effect. We compared the percent excess weight loss (%EWL) of patients divided into two groups based on post-LSG exposure to obesogenic medications. A linear regression model was used to analyze %EWL at 12 months post-LSG while controlling for age, initial body mass index (BMI), and use of leptogenic medications. RESULTS: 150 patients (Meds group) were prescribed obesogenic medications within the one-year post-LSG follow up period, whereas 173 patients (Control group) were not prescribed obesogenic medications. The Meds group lost significantly less weight compared to the Control group (%EWL ± SEM at 12 months 53.8 ± 2.4 n=78, 65.0 ± 2.6, n=84 respectively, P = 0.002). This difference could not be attributed to differences in age, gender, initial BMI, co-morbidities, or prescription of leptogenic medications between the two groups. CONCLUSIONS: The use of provider-prescribed obesogenic medications was associated with worse weight loss outcomes post-LSG. Closer scrutiny of patient medications may be necessary to help improve outcomes of weight loss treatments. |
format | Online Article Text |
id | pubmed-6428627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
record_format | MEDLINE/PubMed |
spelling | pubmed-64286272019-03-21 The effects of provider-prescribed obesogenic drugs on post-laparoscopic sleeve gastrectomy outcomes: A retrospective cohort study Leggett, Cecilia B. Desalermos, Athanasios Brown, Steven D. Lee, Euyhyun Proudfoot, James A. Horgan, Santiago Gupta, Samir Grunvald, Eduardo Ho, Samuel B. Zarrinpar, Amir Int J Obes (Lond) Article BACKGROUND: Laparoscopic sleeve gastrectomy (LSG) is one of the most commonly performed bariatric procedures and has proven effective in providing weight loss. However, considerable variance has been noted in the degree of weight loss. Physician prescription practices may be negatively affecting weight loss post-LSG and, thus, contributing to the broad range of weight loss outcomes. The aim of our study was to determine whether commonly prescribed obesogenic medications negatively affect weight loss outcomes post-LSG. SUBJECTS/METHODS: This single center retrospective cohort study performed at a University hospital included 323 patients (≥18 years) within University California, San Diego Healthcare System who underwent LSG between 2007 and 2016. We identified a list of 32 commonly prescribed medications that have weight gain as a side effect. We compared the percent excess weight loss (%EWL) of patients divided into two groups based on post-LSG exposure to obesogenic medications. A linear regression model was used to analyze %EWL at 12 months post-LSG while controlling for age, initial body mass index (BMI), and use of leptogenic medications. RESULTS: 150 patients (Meds group) were prescribed obesogenic medications within the one-year post-LSG follow up period, whereas 173 patients (Control group) were not prescribed obesogenic medications. The Meds group lost significantly less weight compared to the Control group (%EWL ± SEM at 12 months 53.8 ± 2.4 n=78, 65.0 ± 2.6, n=84 respectively, P = 0.002). This difference could not be attributed to differences in age, gender, initial BMI, co-morbidities, or prescription of leptogenic medications between the two groups. CONCLUSIONS: The use of provider-prescribed obesogenic medications was associated with worse weight loss outcomes post-LSG. Closer scrutiny of patient medications may be necessary to help improve outcomes of weight loss treatments. 2018-09-21 2019-06 /pmc/articles/PMC6428627/ /pubmed/30242239 http://dx.doi.org/10.1038/s41366-018-0207-x Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Leggett, Cecilia B. Desalermos, Athanasios Brown, Steven D. Lee, Euyhyun Proudfoot, James A. Horgan, Santiago Gupta, Samir Grunvald, Eduardo Ho, Samuel B. Zarrinpar, Amir The effects of provider-prescribed obesogenic drugs on post-laparoscopic sleeve gastrectomy outcomes: A retrospective cohort study |
title | The effects of provider-prescribed obesogenic drugs on post-laparoscopic sleeve gastrectomy outcomes: A retrospective cohort study |
title_full | The effects of provider-prescribed obesogenic drugs on post-laparoscopic sleeve gastrectomy outcomes: A retrospective cohort study |
title_fullStr | The effects of provider-prescribed obesogenic drugs on post-laparoscopic sleeve gastrectomy outcomes: A retrospective cohort study |
title_full_unstemmed | The effects of provider-prescribed obesogenic drugs on post-laparoscopic sleeve gastrectomy outcomes: A retrospective cohort study |
title_short | The effects of provider-prescribed obesogenic drugs on post-laparoscopic sleeve gastrectomy outcomes: A retrospective cohort study |
title_sort | effects of provider-prescribed obesogenic drugs on post-laparoscopic sleeve gastrectomy outcomes: a retrospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428627/ https://www.ncbi.nlm.nih.gov/pubmed/30242239 http://dx.doi.org/10.1038/s41366-018-0207-x |
work_keys_str_mv | AT leggettceciliab theeffectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT desalermosathanasios theeffectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT brownstevend theeffectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT leeeuyhyun theeffectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT proudfootjamesa theeffectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT horgansantiago theeffectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT guptasamir theeffectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT grunvaldeduardo theeffectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT hosamuelb theeffectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT zarrinparamir theeffectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT leggettceciliab effectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT desalermosathanasios effectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT brownstevend effectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT leeeuyhyun effectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT proudfootjamesa effectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT horgansantiago effectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT guptasamir effectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT grunvaldeduardo effectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT hosamuelb effectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy AT zarrinparamir effectsofproviderprescribedobesogenicdrugsonpostlaparoscopicsleevegastrectomyoutcomesaretrospectivecohortstudy |